Hologic HOLX earned two key regulatory approvals. The company’s Affirm Contrast Biopsy software has earned the CE Mark, having previously been cleared by the FDA in October 2020. Meanwhile, the Aptima ...
Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback